#1 Clinical Trials Search in Europe

Nanatinostat

Nanatinostat is an experimental drug being studied in clinical trials for the treatment of various cancers associated with the Epstein-Barr virus (EBV). This article explores the ongoing research into Nanatinostat’s potential as a treatment option for EBV-positive solid tumors, lymphomas, and other related conditions. We’ll look at how Nanatinostat works, its combination with other drugs, and the current state of clinical trials investigating its safety and effectiveness.

Table of Contents

What is Nanatinostat?

Nanatinostat, also known as VRx-3996, is a promising new drug being studied for the treatment of various cancers associated with the Epstein-Barr virus (EBV)[1]. EBV is a common virus that infects most people at some point in their lives. While it usually causes no long-term problems, in some cases, it can lead to the development of certain types of cancer.

How Does Nanatinostat Work?

Nanatinostat belongs to a class of drugs called selective class I HDAC inhibitors. It works by activating certain proteins in EBV-infected cancer cells, which then allows another drug called valganciclovir to become toxic to these cells[1]. This combination approach is designed to specifically target cancer cells while minimizing damage to healthy cells.

What Conditions Does Nanatinostat Treat?

Nanatinostat is being studied for the treatment of several EBV-related cancers and conditions, including:

  • Nasopharyngeal Carcinoma: A type of head and neck cancer
  • EBV-Related Gastric Carcinoma: Stomach cancer associated with EBV
  • EBV-Related Leiomyosarcoma: A rare type of soft tissue cancer
  • Other EBV-Related Carcinomas and Sarcomas
  • EBV-Positive Lymphomas: Including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), and post-transplant lymphoproliferative disorder (PTLD)[3]

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of nanatinostat:

  1. Phase 1b/2 Study: This trial is testing nanatinostat in combination with valganciclovir, and in some cases with pembrolizumab (an immunotherapy drug), in patients with advanced EBV-positive solid tumors and recurrent/metastatic nasopharyngeal carcinoma[1].
  2. Mass Balance and Bioavailability Study: This study aims to understand how nanatinostat is processed and eliminated by the body, and how well it’s absorbed when given in different forms[2].
  3. Phase 2 Trial for EBV-Positive Lymphomas: This study is evaluating nanatinostat in combination with valganciclovir for patients with various types of EBV-positive lymphomas that have not responded to or have come back after previous treatments[3].

How is Nanatinostat Administered?

In most clinical trials, nanatinostat is given orally (by mouth) as a tablet. The typical dosage being studied is 20 mg once daily, taken for 4 days each week[1][3]. It’s often given in combination with valganciclovir, which is also taken orally. The exact dosage and schedule may vary depending on the specific trial and the patient’s condition.

Potential Side Effects

As nanatinostat is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring patients for any adverse events. Common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts. Patients in clinical trials are closely monitored for any unexpected side effects[2].

Future Prospects

The development of nanatinostat represents an exciting new approach in the treatment of EBV-related cancers. By specifically targeting cancer cells infected with EBV, this drug has the potential to offer more effective and potentially less toxic treatment options for patients with these challenging cancers. However, it’s important to remember that nanatinostat is still in the investigational stage. More research is needed to fully understand its effectiveness and safety profile before it can be considered for widespread use[1][3].

Aspect Details
Drug Name Nanatinostat (also known as VRx-3996)
Drug Type Selective class I HDAC inhibitor
Target Conditions EBV-positive solid tumors, lymphomas, and related cancers
Combination Therapies Valganciclovir, Pembrolizumab
Administration Oral, typically 20 mg daily for 4 days per week
Trial Phases Phase 1, Phase 1b/2, Phase 2
Primary Outcomes Safety, efficacy, optimal dosing, objective response rate
Secondary Outcomes Duration of response, progression-free survival, overall survival
Trial Status Some trials terminated prematurely, ongoing research

FAQ

  • What is Nanatinostat? Nanatinostat is a selective class I HDAC inhibitor that induces EBV early lytic phase protein generation. It is being studied as a potential treatment for various cancers associated with the Epstein-Barr virus (EBV).
  • What types of cancers are being studied with Nanatinostat? Nanatinostat is being investigated for EBV-positive solid tumors, including nasopharyngeal carcinoma, EBV-related gastric carcinoma, and various EBV-positive lymphomas such as diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
  • How is Nanatinostat administered in clinical trials? In most trials, Nanatinostat is given orally, typically at a dose of 20 mg once daily for 4 days per week in 28-day cycles. However, the exact dosing may vary depending on the specific trial and treatment combination.
  • What other drugs is Nanatinostat being combined with in trials? Nanatinostat is often studied in combination with valganciclovir, which becomes activated to its cytotoxic form when used with Nanatinostat. Some trials are also exploring its use with pembrolizumab, an immunotherapy drug.
  • What are the main goals of the Nanatinostat clinical trials? The primary goals of these trials include evaluating the safety and efficacy of Nanatinostat, determining the appropriate dosage, assessing objective response rates, and measuring outcomes such as progression-free survival and overall survival in patients with EBV-related cancers.

Ongoing Clinical Trials on Nanatinostat

  • Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Epstein-Barr Virus (EBV): A common human herpesvirus that infects most people at some point in their lives. It can sometimes lead to the development of certain cancers.
  • HDAC inhibitor: A class of drugs that block histone deacetylase enzymes, which can affect gene expression and potentially slow or stop the growth of cancer cells.
  • Valganciclovir: An antiviral medication that, when combined with Nanatinostat, becomes activated to a form that can kill cancer cells.
  • Pembrolizumab: An immunotherapy drug that helps the immune system recognize and attack cancer cells.
  • Nasopharyngeal Carcinoma: A type of cancer that occurs in the nasopharynx, which is in the upper part of the throat behind the nose.
  • Lymphoma: A type of cancer that begins in cells of the lymph system, which is part of the body's immune system.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients diagnosed with the disease are still alive.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT05166577
  2. https://clinicaltrials.gov/study/NCT06302140
  3. https://clinicaltrials.gov/study/NCT05011058